Segantii Capital Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Segantii Capital Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-25,000	Closed	-$252K	–	445
2022 Q4	$252K	Hold	25,000	–	–	0.01%	357
2022 Q3	$248K	Hold	25,000	–	–	0.01%	467
2022 Q2	$248	Sell	25,000 -25,000	-50%	-$5.17K	0.01%	455
2022 Q1	$493K	Hold	50,000	–	–	0.01%	366
2021 Q4	$492K	Buy	+50,000	New	+$34.7K	0.02%	360

Segantii Capital Management's BIOTW Position: Q1 2023 in Review

Segantii Capital Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 25,000 shares — an estimated $252K sold.

Segantii Capital Management first reported a position in BIOTW in Q4 2021 and held it in 5 quarters. The position peaked at $493K in Q1 2022. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Segantii Capital Management reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Segantii Capital Management sold 25,000 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $252K.
Segantii Capital Management first reported a position in Biotech Acquisition Company Warrant in Q4 2021 and held it in 5 quarters.
Segantii Capital Management's Biotech Acquisition Company Warrant position peaked at $493K in Q1 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Segantii Capital Management's 13F filing for Q1 2023, filed 5 May 2023.